About the AuthorMy name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.
My ProfileI am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!
About This BlogEye on FDA is published by Mark Senak of FleishmanHillard's Washington, D.C. office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Monthly Archives: October 2009
It is Halloween Weekend. It is also the weekend to Fall Forward and reset the clocks. We are getting closer and closer to the big FDA Social Media Public Meeting on November 12 and 13. By coincidence, or perhaps not, … Continue reading
As the FDA struggles to re-furbish its image, highly tarnished during the last eight years, the CDC provides a lesson in reputation management in its response to the flu pandemic. By many accounts, trust in government is on the decline. … Continue reading
In a document released this Fall, the FDA laid out its Strategic Plan for Risk Communication. As noted in a posting last week, the plan states plainly the need for the FDA to move beyond its traditional parameters because of … Continue reading